A Phase 2 interventional study of Transcranial Magnetic Stimulation (TMS) and Speech-Language Therapy (SLT) in Aphasia, Stroke and Aphasia Following Cerebral Infarction, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University of Pennsylvania · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 175 studies in Aphasia with a site in United States — 49 open to participants now, 59 under way, 1 of them phase 3. Aphasia · United States.
Among the 175 studies in Aphasia with a site in United States, this one is the 75th largest by enrollment of the 158 interventional ones that give a count, is one of 12 that started in 2025, is one of 15 in phase 2, and was the 155th registered.
338 studies on the registry are indexed under Aphasia; 93 are open to participants now.
Browse Aphasia studies →49 of the 175 studies in Aphasia with a site in United States are open now. Recruiting first, the newest first:
Boston University Charles River Campus · Sites in United States
Ages 18–80
University of South Carolina · Sites in United States
Ages 25–80
University of South Carolina · Sites in United States
Ages 18+
Casa Colina Hospital and Centers for Healthcare · Sites in United States
Ages 18+
Maya Henry · Sites in United States
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Aphasia studies recruiting now, 30 (45%) set no upper age limit and 11 (17%) stop at 75 or younger; 1 takes children under 18; 16 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
175 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 3 · Phase 4 1
First in 1992; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is close to the median of 30 across 298 interventional studies indexed under Aphasia.
Median enrollment 30 across the 158 interventional studies, 62 across the 17 observational. Of the 103 that completed or were terminated, 46 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 175 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 8 studies filed under Aphasia — fewer than ten, so there is no comparison to draw.
20 of the studies in Aphasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07036406Teachers College, Columbia UniversityComparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST) | 2026-12 |
| NCT06829420University of South FloridaMirror Speech Entrainment: A Novel Technique for Voice Personalized Speech Entrainment for Nonfluent Aphasia | 2026-12-31 |
| NCT04142866City University of New YorkTranscranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia | 2026-12-31 |
| NCT04682223University of South CarolinaTelerehabilitation for Aphasia (TERRA) | 2027-01 |
| NCT07563387University of FloridataVNS for Speech and Language Recovery in Aphasia | 2027-01-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 175 studies in Aphasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine if Transcranial Magnetic Stimulation (TMS) combined with Speech-Language Therapy (SLT) is an effective treatment for mild aphasia in persons with chronic stroke.
The main questions this study aims to answer are:
Researchers will compare real TMS to sham (fake) TMS to see whether TMS can treat post-stroke mild aphasia.
Participants will:
Aphasia is an acquired disorder of language that occurs in approximately 30% of individuals with stroke and impacts approximately 1 million Americans (see NINDS.NIH.gov). Current treatments for aphasia are only modestly beneficial, so there is a clear need for more efficacious therapy.
Previous research has demonstrated that TMS improves language performance in persons with aphasia and the benefit has been shown to be sustained. All studies of which we are aware, however, have included participants with moderate/severe aphasia. The issue of mild aphasia has received little attention to date but as there is an increasing recognition that even very mild language deficits have important negative consequences for employment and social well-being. This study will aim to treat mild aphasia with TMS and SLT emphasizing conversations speech.
One limitation of TMS has been variability in response; TMS has shown good within-subject reliability but more substantial variability between subjects. In recognition of these issues, "electrical field" (e-field) models have been developed to account for these individual differences in anatomy. We will the utilize e-field models in conjunction with an individually determined resting motor threshold to generate a personalized treatment regimen that is likely to ensure that all subjects receive the same TMS intensity relative to their individual motor threshold and greatly reduces the possibility of under- or over-dosing with respect to TMS intensity. We will employ continuous theta-burst stimulation, 600 brief electrical pulses delivered in 40 seconds, over the right front part of the brain (pars triangularis).
Participants who are enrolled can expect to undergo a battery of tests to define their language function as well as a research MRI scan that will be used to guide TMS therapy and to assess the size and location of the stroke and its impact on brain pathways. After baseline testing, subjects will undergo treatment using TMS (or sham) + SLT for 10 sessions (Monday-Friday) over the course of 2 consecutives week. Follow-up assessment of language functioning will be assessed immediately, 2 months and 4 months after treatment.
Participants will be compensated for their time and travel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Some of our participants will be randomized to the real treatment arm where they will receive 10 sessions of real TMS paired with speech-language therapy.
Device: Transcranial Magnetic Stimulation (TMS) · Behavioral: Speech-Language Therapy (SLT)
Some of our participants will be randomized to the sham treatment arm where they will receive 10 sessions of fake TMS paired with speech-language therapy.
Behavioral: Speech-Language Therapy (SLT)
TMS, is a form of non-invasive brain stimulation, that uses magnetic pulses to stimulate specific areas of the brain. In this study we will utilize theta-burst stimulation which uses a higher frequency pulse of 50 Hz delivered for 40 seconds for a total of 600 pulses.
Our SLT protocol draws from two theories and evidence-based cognitive-linguistic frameworks: (1) conversational alignment, which engages priming of lexical and syntactic structures through dialogue and conversation and (2) increased tolerance of memory load in the context of sentence repetition and dialogue tasks. Administration of these tasks will abide by principles of constraint-induced language therapy, i.e., intense treatment schedule and verbal responding only. All participants will receive SLT.
Sentence Processing
Change in performance on the Temple Assessment of Language and Short-term Memory in Aphasia (TALSA) sentence processing composite score.
Time frame: From baseline to 4 months post-intervention
Semantic and Phonological Processing
Change in performance on the TALSA composite semantic processing score and phonological processing score.
Time frame: From baseline to 4 months post-intervention
Elicited Speech
Change in performance on the Nicholas \& Brookshire picture description and Story Retell scores.
Time frame: From baseline to 4 months post-intervention
Plan to share: No — No, the study team does not plan to share participating data at this time.
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Oct 2026, 20 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.